The Nipah virus disease is a lethal infection that has led to 40% to 75% fatalities in Malaysia, 10 Bangladesh and India. The reports of human-to-human transmission documented in Bangladesh 11 has raised the specter of pandemic potential and has caused the World Health Organization to list 12 the Nipah virus as one of the pathogens to be considered for development of drugs and vaccines 13 on urgent basis, neither of which exist against the Nipah virus as of now, although many 14 proposals have been made and trials initiated. Given that there are established country-specific 15 differences in the virus' effects and fatalities, meeting the sudden need for a vaccine in case of an 16 epidemic will require design, development and preparation for a peptide vaccine. Thus, we 17 propose a protocol for creating peptide vaccines that can be tailor-made for these specific 18 countries, an approach which is being advocated for the first time. Here, we analyze the surface 19 proteins, Fusion protein and Glycoprotein, of the strains currently affecting the three countries on 20 a large scale and determine the specific country-based epitope differences.
Introduction situated G protein as the most appropriate target since it is responsible for attachment to the 115 ephrin receptor in host cells. Since the Nipah viral sequence showed very strong, long stretches 116 of conserved domains that matched HeV's conserved stretches also, it was natural to club the 117 two together to design a common vaccine that matched all our criteria. Using our protocol, we 118 identified conserved segments on the viral protein which are sufficiently surface exposed, 119 determined their epitope potential in the host population and tested for auto-immune threats. We 120 report here on the results for the peptide targets for the Malaysian, Bangladeshi and Indian 121 (Keralite) populations as a ready guide for developing appropriate vaccines. Such overall 122 country/community-wise epitope search is, to the best of our knowledge, being reported for the 123 first time. 125 We downloaded all the available complete sequences of the Nipah virus glycoprotein (20) and 126 the Hendra virus glycoprotein (15) and the Nipah glycoprotein structure, 2VWD, from the NCBI 127 databases. 128 For numerical comparison of protein sequences, we used a sequence representation described 129 earlier [27] where in a rectangular co-ordinate system of 20-dimensions each amino acid is 130 associated with a particular direction and the protein sequence is plotted by taking successive 131 steps in the directions dictated by the amino acids. This generates a plot in an abstract space, but 132 we can define a weighted center of mass and a protein graph radius, p R . The special property of 133 p R is that in each case when two sequences result in the same graph radius the sequences are 134 found to be identical (28). Using a n-amino acid window (n < N, the total length of the protein 135 sequence) and sliding it along a sequence we can compare the values of p R at each window 136 position for a set of sequences; where the p R remain constant through all sequences for the same 137 window position, or change very little, we can assume the peptide belonging to that window is 138 reasonably well conserved. This property has been used in several instances previously [21] [22] [23] [24] [25] 139 27]. In this procedure specifically, the protein sequence is mapped using a window of 12 to 14 140 amino acids and sliding in increments of one amino acid (aa) at a time. At each stage the peptide 141 graph radius, p R , is computed [27] and stored until the end of the sequence is reached. This is 142 then repeated for each protein sequence of the selected group of sequences and then the entire lot 143 is scanned at each mapped aa position to determine the number of different p R values amongst all 144 the sequences. Since each p R value represents a particular peptide sequence, the number of these 145 values at each aa position map out a protein variety profile along the sequence; a moving average 146 over 12 windows' values make for easy viewing on a plot whose minima indicate regions where 147 variety, and by inference changes in amino acids, are relatively least indicating most conserved 148 regions.
124

Materials and Methods
149
In this analysis we have used a peptide window size of 12 amino acids. In one of our earlier 150 analysis with the neuraminidase protein [21] we had considered peptide lengths of 8, 10 and 12 151 amino acids; for rotavirus where mutational changes occur very frequently, we used window 152 sizes of 12 to 14 amino acids [22] ; 14 residue peptides were found to be more potent 153 antigenically compared to smaller peptides [29] and we had used that size for analysis of 154 influenza hemagglutinin [23] . We note that while peptides of 6 to 20 amino acids lengths are 155 used in scanning for B-cell epitopes, peptides of 10+ residues may contain overlapping linear B- Hendra viruses are RNA type which therefore is comparatively less stable, we fixed window 159 length for this exercise at 12 amino acids.
160
The protein sequences are next mapped for solvent accessibility through an Average Solvent 161 Accessibility (ASA) server such as SABLE or ITASSER or any other suitable web-based 162 servers. Taking a moving average over 12 amino acids of solvent accessibility index, and 163 averaging over several sequences for each virus type, this is mapped out to reveal by the crests 164 on the graph the most solvent accessible regions.
165
Mapping both the graphs, peptide variability profile and solvent accessibility profile, together, 166 we search for those regions where the protein variability is at a minimum and solvent 167 accessibility is among the highest. These selected regions make up the first list of conserved 168 solvent accessible segments of the protein.
169
To confirm that the regions identified in the previous step are indeed surface situated, we 170 examine the identified regions in a protein 3D structure through PyMol software. Marking out 171 the identified segments on one protein of the 3D structure will reveal how much of the segments 172 lie on the surface; availability of nearby structures will reveal if these structures cover part or all 173 of the selected segment(s).
174
Next, we consider which of the segments contains epitope regions both linear and discontinuous 175 to elicit necessary immune response. For this we use the IEDB (Immune Epitope Database and To see whether our selected peptide regions can act as epitopes and can able to elicit necessary 181 immune response, we use another epitope-prediction tool ABCpred server 182 (http://www.imtech.res.in/raghava/abcpred/ABC_submission.html) [36] . These tools indicate 183 binding affinities of B-cell epitopes (with 66% accuracy). 184 We also needed to analyze the role of human MHC polymorphism in the Nipah disease severity. Table 1 . Using the 2VWD crystal structure from the Protein Data Base (PDB) we determined that regions 206 3 and 4 above are peptides that are highly surface exposed (Fig.2) ; while we show the peptides 207 on one monomer of the dimeric structure, it is clear that those are not covered by the neighboring 208 protein. Unfortunately, since the PDB structure starts from aa number 187, we could not visually 209 demonstrate that regions 1 and 2 are also surface exposed, but on the basis of the ASA profile 210 graph of Fig.1 and the evidence with regions 3 and 4, we assume that regions 1 and 2 are solvent 211 accessible, although we have no information as of now whether the neighboring protein will 212 cover them or not.
213
The next step was to search for existence of linear and conformational epitope regions within the 214 identified segments so that we can in the current instance identify such epitopes and expect 215 suitable adjuvants to enhance the immune response [17] . Our interest being generation of 216 antibody response to the invading pathogens, we concentrate on MHC Class II molecules that 217 mediate establishment of humoral immunity.
218
Using the IEDB server to determine the binding affinities for Human Leukocyte Antigens 15 residues. We select the peptides encompassing the identified group (Table 1) with a latitude 234 of 4 to 5 residues to ensure good binding with the HLA alleles while remaining within the 235 requirements of reasonably well conserved regions and high ASA; references to the crystal 236 structure ensures the peptides are still surface exposed even if they are slightly adjusted from the 237 regions as per Table 1 .
238
The HLA-DRB alleles, which are the dominant types, are shown in Table 2a between. All regions show one or more alleles with good binding, region 4 just outside the 10-244 percentile rank for all 3 countries. All peptides of regions 3 and 4 (aa numbers 300+) were found 245 to be surface exposed except for last two residues of Malaysian region 3 peptide ( Table 2a except for a small displacement in region 3. This region showed the 255 best results for the DP/DQ alleles amongst all the regions. The results for the other regions are 256 the best available for the surface exposed conserved segments we are interested in. As a further check on our selection of epitopes for the four regions of the viruses from the three 278 countries, we determined the B-cell binding efficiencies using the ABCpred server. The 279 summary results are given in Table 3 which shows that among the high binding efficiency 280 epitopes predicted by ABCpred, all our determined epitope regions occur for all countries with 281 high scores indicating good epitope potential.
282 The peptide sequences we determined to be conserved surface exposed with good epitope 300 potential were all tested for auto-immune threats by doing a protein-protein BLAST but no 301 homology was found for any human proteins. Table 5 summarizes the 15-mer peptide results for 302 these epitopes and could form a basis for eventual design of peptide vaccines, which ideally 303 could be different for the different countries analyzed here.
304 Thus, the results of our bioinformatics analyses reported above show that there are sufficient 309 grounds for considering peptide vaccines as anti-viral agents against the Nipah and Hendra 310 viruses. However, no peptide vaccines have been licensed as yet for human use, and the gap 311 between the in silico designed vaccine candidates in the computer and the doctor's use of the real 312 vaccine in patients as the preventive tool against the viral disease is a long and tortuous one. In 313 the case of the Zika virus where world attention was rivetted due to deformed births there have 314 been many peptide vaccines in various phases of trials, but as yet no definitive conclusions have 315 been arrived at. One of the difficulties in getting large scale trials going is that the epidemic has 316 petered out [15] . Similarly, in the case of Nipah where the illnesses have been sporadic and 317 localized, such trials would be even more difficult to conduct, no matter how important this step 318 is for licensure. Trials with animal models remain the only recourse as a preparatory measure 319 against a future need. While such trials have been reported for different types of vaccines against 320 the Nipah virus as mentioned in the Introduction, these are all "one size fits all" type of vaccines.
321
What we are advocating here are peptide vaccines that can be tailor-made to suit individual 322 countries' populations, which will be entirely possible on a "manufacturing" kind of scenario, 323 something that is not possible, or would take an inordinately long time, with live-attenuated or 
